Interleukin 17A: a Janus-faced regulator of osteoporosis

[1]  K. Akashi,et al.  CCR6+ group 3 innate lymphoid cells accumulate in inflamed joints in rheumatoid arthritis and produce Th17 cytokines , 2019, Arthritis Research & Therapy.

[2]  J. Gustafsson,et al.  ERα expression in T lymphocytes is dispensable for estrogenic effects in bone , 2018, The Journal of endocrinology.

[3]  C. Ritchlin,et al.  Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions , 2018, Calcified Tissue International.

[4]  Jill O Jin.  Hormone Therapy for Primary Prevention of Chronic Conditions in Postmenopausal Women. , 2017, JAMA.

[5]  F. Blanco,et al.  Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study , 2017, Arthritis & rheumatology.

[6]  R. Baron,et al.  Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. , 2017, Cell metabolism.

[7]  Y. Fujiwara,et al.  RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice* , 2016, The Journal of Biological Chemistry.

[8]  J. Mulle,et al.  Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. , 2016, The Journal of clinical investigation.

[9]  Guang-bin Wang,et al.  Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis , 2015, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[10]  R. Baron,et al.  Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures , 2014, Nature Medicine.

[11]  R. Trivedi,et al.  Enhanced Immunoprotective Effects by Anti‐IL‐17 Antibody Translates to Improved Skeletal Parameters Under Estrogen Deficiency Compared With Anti‐RANKL and Anti‐TNF‐α Antibodies , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  P. Gümüş,et al.  Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease. , 2013, Journal of periodontology.

[13]  R. DePinho,et al.  Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. , 2013, Cell metabolism.

[14]  Vilmundur Gudnason,et al.  Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  G. Frühbeck,et al.  Peripheral signalling involved in energy homeostasis control , 2012, Nutrition Research Reviews.

[16]  R. Trivedi,et al.  Estrogen Deficiency Induces the Differentiation of IL-17 Secreting Th17 Cells: A New Candidate in the Pathogenesis of Osteoporosis , 2012, PloS one.

[17]  W. Zou,et al.  IL‐17 mediates estrogen‐deficient osteoporosis in an Act1‐dependent manner , 2012, Journal of cellular biochemistry.

[18]  Heather Ting Ma,et al.  Bone marrow fat content in the elderly: A reversal of sex difference seen in younger subjects , 2012, Journal of magnetic resonance imaging : JMRI.

[19]  J. Penninger,et al.  Lineage‐committed osteoclast precursors circulate in blood and settle down into bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  E. Butcher,et al.  IL-17 Regulates Adipogenesis, Glucose Homeostasis, and Obesity , 2010, The Journal of Immunology.

[21]  C. Tato,et al.  Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.

[22]  C. Tato,et al.  Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.

[23]  Yong Liu,et al.  Assessment of bone marrow changes in postmenopausal women with varying bone densities: magnetic resonance spectroscopy and diffusion magnetic resonance imaging. , 2010, Chinese medical journal.

[24]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[25]  S. Gaffen,et al.  A bone‐protective role for IL‐17 receptor signaling in ovariectomy‐induced bone loss , 2009, European journal of immunology.

[26]  Yuuki Imai,et al.  Estrogens Maintain Bone Mass by Regulating Expression of Genes Controlling Function and Life Span in Mature Osteoclasts , 2009, Annals of the New York Academy of Sciences.

[27]  K. Ley,et al.  IL-17A Controls IL-17F Production and Maintains Blood Neutrophil Counts in Mice1 , 2009, The Journal of Immunology.

[28]  P. Baldock,et al.  Leptin as an endocrine signal in bone , 2008, Current osteoporosis reports.

[29]  J. Risteli,et al.  Short-Term Changes in Serum PINP Predict Long-Term Changes in Trabecular Bone in the Rat Ovariectomy Model , 2008, Calcified Tissue International.

[30]  B. L. Riggs,et al.  Effect of Blockade of TNF‐α and Interleukin‐1 Action on Bone Resorption in Early Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  S. Nakae,et al.  Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1 , 2003, The Journal of Immunology.

[32]  L. Joosten,et al.  IL-17 Promotes Bone Erosion in Murine Collagen-Induced Arthritis Through Loss of the Receptor Activator of NF-κB Ligand/Osteoprotegerin Balance 1 , 2003, The Journal of Immunology.

[33]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[34]  I. Homma,et al.  Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. , 2002, Immunity.

[35]  G. Karsenty,et al.  The osteoblast: a sophisticated fibroblast under central surveillance. , 2000, Science.

[36]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[37]  Arndt F Schilling,et al.  Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.

[38]  J. Gustafsson,et al.  Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. , 1999, The Journal of clinical investigation.

[39]  M. K. James,et al.  The Relationship of Biochemical Markers of Bone Turnover to Bone Density Changes in Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[41]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[42]  S. Nozawa,et al.  Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. , 1994, The Journal of clinical investigation.

[43]  E. Puscheck,et al.  Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Albright,et al.  POSTMENOPAUSAL OSTEOPOROSIS: ITS CLINICAL FEATURES , 1941 .

[45]  Y. Fujiwara,et al.  RANKL Produced by Osteocytes is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice , 2016 .

[46]  S. Takeda.  The Central Control of Bone Mass , 2013 .

[47]  K. Wakasa,et al.  Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours , 2005, Virchows Archiv A.

[48]  J. Reginster,et al.  Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. , 1997, Maturitas.

[49]  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. , 1996, JAMA.